1 Luteolin transforms the BMDM polarity to regulate the expression of 2 inflammatory factors

3 Shuxia Wang,^a Shuhang Xu,^b Meng Cao,^c; Jing Zhou,^c Xiaodong Mao,^b Xiaoming Yao,^a Chao
4 Liu,^b

5 ^aClinical Laboratory, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,
6 Nanjing University of Chinese Medicine; Jiangsu Province Academy of Traditional Chinese
7 Medicine, Nanjing, Jiangsu, China

8 ^b Research Center of Endocrine and Metabolic Diseases, Affiliated Hospital of Integrated
9 Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine; Jiangsu
10 Province Academy of Traditional Chinese Medicine, Nanjing, Jiangsu, China

11 ^c Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University
12 of Chinese Medicine, Nanjing, Jiangsu, China

13 Address correspondence to Xiaoming Yao and Chao Liu: Yaoxm73@163.com;
14 profliuchao@163.com

15 **ABSTRACT** Macrophage are indispensable regulator cells in inflammatory response.
16 Macrophage polarization and its secreted inflammatory factors have affinity with the outcomes of
17 inflammation. Luteolin, a flavonoid abundant in plants has anti-inflammatory activity, but whether
18 luteolin can manipulate M1/M2 polarization of BMDM to suppress inflammation is still veiled.
19 The purpose of this study was to observe the effects of luterolin on the polarity of BMDM derived
20 from C57BL/6 mice and the expression of inflammatory factors, to explore the mechanism of

luteolin regulating the BMDM polarity. M1-polarized BMDM were induced by LPS+IFN- γ , M2-polarization were stimulated with IL-4. BMDM morphology was observed by laser confocal microscopy; levels of BMDM differentiation and CD11c or CD206 on membrane surface were assessed by FCM; mRNA and protein of M1/M2-type inflammatory factors were performed by qPCR and ELISA, respectively; the expression of p-STAT1 and p-STAT6 protein pathways was detected by Western-blotting. The isolated mouse bone marrow cells were successfully differentiated into BMDM, LPS+IFN- γ induced BMDM M1-phenotype polarization, and IL-4 induced its M2-phenotype polarization. After M1-polarized BMDM treated with luteolin, M1-type pro-inflammatory factors including IL-6, TNF- α , iNOS, CD86 were down-regulated while M2-type anti-inflammatory factors including IL-10, Arg1, CD206 were up-regulated; the expression of M1-type surface marker CD11c decreased, nevertheless, M2-type marker CD206 increased; levels of inflammatory signaling protein p-STAT1 and p-STAT6 were attenuated and enhanced respectively. Our study suggests luteolin may transform BMDM polarity through p-STAT1/6 to regulate the expression of inflammatory mediators, thereby inhibiting inflammation. Naturally occurring luteolin hold promise as an anti-inflammatory and immunomodulatory agent.

KEYWORDS: cytokines, inflammation, BMDM polarization, luteolin

Inflammation is the immune system's response to invading pathogens, but aberrant inflammation responses leads to a “cytokine storm” that makes patients sicker (1). Mounting evidences found that continuous and/or repeated inflammatory stimuli could also induce tumors (2). Therefore, the inflammatory response is a double-edged sword. If immune cells and pro-inflammatory cytokines are overproduced, cytokine cascades occur, called “cytokine storm” or termed as “inflammatory storm”, leading to sepsis, acute respiratory distress syndrome (ARDS)

and even multiple organ failure (MOF) (3). As well all know, pathogenic agents such as viral or bacterial infections incur the pathological process of sepsis which is characterized by an overwhelming generation of pro-inflammatory cytokines. Recently, global pandemic of coronavirus disease 2019 (COVID-19) suffering from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is also associated with macrophage hyperpolarization elicits “cytokine storms” and viral sepsis (4). Thus, the immunomodulatory therapy of inflammation is crucial for maintaining homeostasis (5-6).

Macrophages have been identified as critical effector cells in inflammatory/immune response and can be activated by pathogenic agents or inflammatory mediators to secrete various inflammatory factors. Meanwhile, heterogeneity and plasticity are hallmarks of macrophages, that is, M1-polarized (pro-inflammatory) macrophages and M2-polarized (anti-inflammatory) macrophages. Pathogens infection can polarize macrophages to M1-phenotype, produce high level of pro-inflammatory cytokines such as IL-6 and TNF- α , or effector molecules iNOS and surface markers CD11c or CD86, exert a pro-inflammatory effect and defense against pathogens. Conversely, IL-4 or TGF- β induced M2-phenotype macrophages mainly express anti-inflammatory cytokine IL-10, effector molecule Arginase (Arg) 1 and surface marker CD206, contribute to hinder inflammation (7). Normally, the M1/M2 polarization of macrophages maintains a dynamic equilibrium. When virulent bacteria or viral infections or overmuch inflammatory molecules irritation, this balance is disrupted, excessive M1 polarization of macrophages will generate redundant inflammatory factors, causing systemic inflammatory response syndrome (SIRS, namely sepsis) and MOF (8). Therefore, it is particularly vital to skew the macrophage polarization and avoid excessive M1-polarization, thus reduce the inflammatory

65 response and promote tissue remodeling.

66 At present, most anti-inflammatory agents are glucocorticoids, antibiotics or antivirals.
 67 Hormones not only produce immunosuppression, but also induce secondary infections and
 68 prolong the disease course or other side effects. Antibiotics or antiviral drugs only kill the
 69 pathogen, and that antibiotics lyse the bacteria while killing the bacteria, releasing more toxins to
 70 induce "cytokine storms", further exacerbating the inflammatory response and promoting the
 71 promoting factor to the development of sepsis. In this regard, natural anti-inflammatory immune
 72 drugs extracted from plants have multi-effect regulation and less toxic, and especially have
 73 obvious benefits in suppressing inflammation. Therefore, it is urgent to seek natural compounds
 74 with high efficiency and low toxicity as anti-inflammatory immune agents.

75 Luteolin (Lut) is a flavonoid, mainly exists in fruits, vegetables and Chinese herbs, which has
 76 anti-hyperlipidemia (9), antitumor (10), anti-inflammation and immunoregulation (11). Studies
 77 showed that luteolin also has antiviral effects against Influenza A virus or dengue virus by
 78 interfering with coat protein (12-13). Recently research indicated that active ingredients of
 79 Chinese medicines including luteolin, quercetin etc. could manage COVID-19 by targeting on
 80 AEC2 and 3CL protein and dampen inflammatory mediators without side effects and have
 81 achieved significant clinical efficacies (14). Our previous investigation found that luteolin can
 82 regulate the expression of inflammatory factors in macrophages and play an anti-inflammatory
 83 role (7), but whether luteolin can regulate the polarization of macrophages and its molecular
 84 mechanism is still veiled. In this research, bone marrow cells isolated from C57BL/6 mice were
 85 induced to differentiate into bone marrow-derived macrophages (BMDM) for investigating the
 86 effects of luteolin on the M1/2 polarization of BMDM and the expression of inflammatory factors

so as to explore the underlying mechanism. Our present findings preliminary provided luteolin could be a future perspective for the natural anti-inflammatory agent in prevention and treatment of sepsis.

MATERIALS AND METHODS

Mice. 6-week-old C57BL/6 mice (weighting 18-22 g) were provided from animal experimental center of affiliated hospital of integrated traditional Chinese and Western medicine, Nanjing University of Chinese medicine (Nanjing, China). Mice were maintained under specific pathogen-free conditions and in accordance with protocols approved by the National Institute of Health Guide for Care (Ethics Number: AEW-20181019-53).

Isolation and culture of BMDM. C57BL/6 mice were sacrificed by cervical dislocation, and dissected under immersion in 75% ethanol (V/V). The epiphysis was cut after tibia and femur were separated, and the bone marrow cavity was rinsed with sterile PBS until the bone became white. The bone marrow washing solution was filtered with a 70 μ m mesh and transferred to a 50 mL centrifuge tube for cell collection. After lysis of red blood cells, bone marrow stem cells were resuspended in DMEM (Gibco, USA) containing 20 ng/mL M-CSF (R&D System, USA) on 10-cm petri dishes and renewed the medium every other day. After 7 days incubation, cells were labeled with F4/80-PE fluorescently conjugated antibodies (1.0 μ L; eBioscience, USA) to identify the differentiation degree of mature BMDM by FCM (Millipore, USA).

Cell viability assay. BMDM were plated in 96-well plates at a density of 2×10^4 cells/well in 200 μ L medium with confluence overnight. After that, the cells were exposed with LPS (20 ng/mL; Sigma, USA) plus IFN- γ (10 ng/mL; PeproTech, USA) or IL-4 (20 ng/mL; Pepro Tech, USA),

and LPS plus IFN- γ -primed cells were administrated with luteolin (Sigma, USA) at 2.5 and 5.0 $\mu\text{mol/L}$ for 24 h. Following treatment, cells were added with 20 μL MTT solution (5 mg/mL; Sigma, MO. USA). 4 h later, culture medium was removed and crystals were dissolved with 150 μL /well DMSO. The absorption values were measured at 570 nm.

The morphology of polarized BMDM. BMDM in logarithmic stage were cultivated in 6-well plates, and incubated overnight followed by treatment with LPS (20 ng/mL) plus IFN- γ (10 ng/mL) or IL-4 (20 ng/mL). Simultaneously, the cells stimulated with LPS+IFN- γ were co-cultured with specified concentrations of luteolin for 24 h. The cell morphology was observed under an inverted microscope (Olympus, Japan). Cells and culture supernatants were collected for subsequent mRNA and protein analysis.

Quantitative real-time PCR (qPCR). BMDM were stimulated with LPS plus IFN- γ or IL-4 respectively, following dosing stimuli, cells were collected and total RNA was extracted by Trizol (Ambion Life Technology, USA) and reverse-transcribed into cDNA. With GAPDH as the internal reference, qPCR was carried out using SYBR Green Master Mix (Toyobo, Japan) according to primer sequences with Quant studio DX real-time quantitative PCR employed biosystems (Life Technologies, USA). Relative gene expression was calculated using the $2^{-\Delta\Delta\text{Ct}}$ comparative method. Primer Sequences were obtained from Generay Biotech Co. Ltd. (Shanghai, China) and listed in Table 1.

Table 1. Primers for quantitative real-time PCR

Genes	Forward (5'-3')	Reverse (5'-3')
-------	-----------------	-----------------

CD86	TCAATGGGACTGCATATCTGCC	GCCAAAATACTACCAGCTCACT
iNOS	CAGAGGACCCAGAGACAAGC	TGCTGAAACATTTCTGTGC
IL-6	TAGTCCTTCCTACCCCAATTTC	TTGGTCCTTAGCCACTCCTTC
TNF-α	CCTCCCTCTCATCAGTTCTA	ACTTGGTGGTTTGCTACGAC
Arg1	CAGAAGAATGGAAGAGTCAG	CAGATATGCAGGGAGTC
CD206	CAGGTGTGGGCTCAGGTAGT	TGTGGTGAGCTGAAAGGTGA
IL-10	CTTACTGACTGGCATGAGGATCA	GCAGCTCTAGGAGCATGTGG
GAPDH	TGAAGCAGGCATCTGAGGG	CGAAGGTGGAAGAGTGGGAG

127 **ELISA for cytokines secretion.** BMDM in exponential phase were inoculated in a six-well plate
128 overnight. Successively, the drugs induced cell polarization and combined with different
129 concentrations of luteolin for 24 h. The levels of cytokines in the supernatants were performed
130 according to commercial ELISA kit (eBioscience, USA) instructions. Logistic fitting-curve for
131 two of four parameters was used to calculate the concentration of cytokines.

132 **Flow Cytometric Staining of BMDM surface Markers.** Totally, 5×10^5 BMDM were
133 resuspended in 100 μ L PBS, then incubated with 0.5 μ L anti-mouse CD16/32 blocking antibody
134 (BioLegend, San Diego, USA) to avoid nonspecific binding in an ice bath for 20 min.
135 Subsequently, cells were stained with anti-mouse FITC-CD11c (0.5 μ L; BioLegend) or
136 APC-CD206 (10 μ L; BioLegend) and protected from exposure to light for 30 min at room
137 temperature. After washing with PBS, the cells were fixed with 0.5 mL paraformaldehyde at 4°C,
138 and the mean fluorescence intensity (MFI) of membrane surface antigen CD11c or CD206 were
139 analyzed by FCM.

Protein extraction and immunoblotting. Collect cells and extract total protein for protein quantification by BCA. After 20 µg protein was subjected to SDS-PAGE and transferred to PVDF membrane (millipore, USA), the corresponding primary antibodies against p-STAT1-tyr⁷⁰¹, p-STAT6-tyr⁶⁴¹ (Cell Signaling Technology, USA) and β-actin (Sigma, USA) were applied at 4°C overnight. Then membranes were washed and incubated with HRP-conjugated secondary antibodies with shaken at room temperature for 30 min. Immunoreactive proteins were exposed and developed using ECL (Beyotime, China), and β-actin was used as an internal reference to calculate the relative expression of protein.

Statistical analysis. The experimental data were presented as mean ± SD. One-way ANOVA followed by Tukey's post-hoc test was used in the multiple comparisons. Analysis was performed using the GraphPad Prism 5.0 software (San Diego, CA, USA). *P* < 0.05 was considered statistically significant.

RESULTS

Mouse bone marrow cells differentiate into macrophages. The isolated mouse bone marrow cells were induced by M-CSF for 7 days, and FCM detected the specific marker F4/80 of mouse macrophages. The results showed that the purity of the differentiated macrophages reached 92.71%, indicating that the BMDM derived from mouse bone marrow were successfully cultured and could be used in subsequent experiments (Fig. 1).

FIG 1 The differentiation proportion of BMDM. FCM detected the surface marker F4/80 of BMDM after induction for 7 days, and the positive rate was 92.71%.

Effect of luteolin on BMDM viability. The non-cytotoxic doses of luteolin were evaluated via MTT assay to exclude contribution of anti-inflammatory potential of luteolin. Luteolin exhibited no significant impact on the LPS+IFN- γ -primed BMDM proliferation at concentration up to 5.0 μ M at 24 h (Fig. 2 B). Therefore, non-cytotoxic concentration was chosen to assess the bioactivity of luteolin.

FIG 2 Effect of luteolin on LPS+IFN- γ -primed BMDM viability. A. Structure of luteolin. B. BMDM were primed with LPS+IFN- γ and contributed with indicated doses of luteolin for 24 h, then the cell viability was assessed by MTT assay. Data represented mean $\pm$ SD of three independent experiments performed in triple. Different symbols indicate a significant difference

according to ANOVA and Tukey test. $*P < 0.05$ vs. control group (non-treated control); $^{\&}P < 0.05$

vs. LPS+IFN- γ -treated group.

Morphology of polarized BMDM. Microscopically, BMDM showed typical morphology of macrophages, such as round, oval or irregular shape, with pseudopods and adherential growth (Fig. 3. Control group). After being induced into M1-phenotype by LPS plus IFN- γ , the BMDM presented oval "Fried egg" appearance and pseudopodia extension (Fig. 3. LPS+IFN- γ -treated group), while the M2-type BMDM induced by IL-4 were round and plump cytoplasm, accompanied by short pseudopodia (Fig. 3. IL-4-treated group). After various dose of luteolin contribution, M1 cells contracted slightly and pseudopodia became shorter (Fig. 3. LPS+IFN- γ -combined with 2.5/5.0 Lut-treated groups).

181

182 **FIG 3** The morphology of polarized BMDM (A. 100×; B. 200×). BMDM were polarized with
183 LPS+IFN-γ or IL-4, simultaneously, BMDM exposed to LPS+IFN-γ were administrated with
184 luteolin for 24 h. Micrographs of BMDM were observed using bright field Olympus imaging
185 system.

186 **Effect of luteolin on mRNA expression of inflammatory factors in polarized BMDM.** The
187 expression of M1-type and M2-type proinflammatory factors were detected by qPCR. Results
188 implied that the expression of M1-type pro-inflammatory factors in M1-polarized BMDM such as
189 CD86, iNOS, TNF-α and IL-6 was up-regulated; the expression of M2 type anti-inflammatory
190 factors such as CD206, Arg1 and IL-10 in M2-polarized BMDM also up-modulated. This
191 indicates that the polarization models of BMDM were successfully induced. When M1 cells were

combined with luteolin, the expression of M1-type pro-inflammatory factors were decreased (Fig. 4), while the expression of M2-type anti-inflammatory factors were increased (Fig. 5).

FIG 4 Effect of luteolin on the expression of M1-type pro-inflammatory factors in activated BMDM. The M1-type mRNA molecules were determined by qPCR with GAPDH as an internal control. BMDM were primed with LPS+IFN-γ or IL-4, and LPS+IFN-γ-treated-BMDM incubated with indicated doses of luteolin for 24 h, the relative M1-type mRNA levels of CD86 (A), iNOS (B), IL-6 (C) and TNF-α (D) in M1-polarized macrophages reduced slowly. Data represented mean ± SD of four independent experiments performed in duplicate. Different symbols indicate a significant difference according to ANOVA and Tukey test. * $P < 0.05$, ** $P < 0.01$ vs. control group (non-treated control); & $P < 0.05$ vs. LPS+IFN-γ-treated group.

FIG 5 Effect of luteolin on the expression of M2-type anti-inflammatory factors in activated BMDM. The M2-type mRNA molecules were assessed by qPCR with GAPDH as an internal control. BMDM were primed with LPS+IFN- γ or IL-4, and LPS+IFN- γ -treated BMDM incubated with indicated doses of luteolin for 24 h, the relative M2-type mRNA levels CD206 (A), Arg1 (B) and IL-10 (C) elevated gradually. Data represented mean $\pm$ SD of four independent experiments performed in duplicate. Different symbols indicate a significant difference according to ANOVA and Tukey test. * P < 0.05, ** P < 0.01 vs. control group (without treatment); [&] P < 0.05 vs. LPS+IFN- γ -treated group.

Effect of luteolin on inflammatory cytokine levels in polarized BMDM. To further explore the polarity skewing effect of luteolin in BMDM, IL-6 and IL-10 production were measured with ELISA. Pro-inflammatory cytokine IL-6 liberated by M1-polarized BMDM increased significantly, in the meantime, anti-inflammatory cytokine IL-10 secreted by M2-polarized BMDM also amplified clearly, which was statistically different from the control group (without treatment). After various dose of luteolin challenged to M1-polarized BMDM, IL-6 released by M1-polarized BMDM lowered visibly, while IL-10 elevated obviously, compared with corresponding LPS+IFN- γ -treated group, there was a statistical difference (Fig. 6).

FIG 6 Effect of luteolin on IL-6 and IL-10 levels in polarized BMDM. BMDM were primed with LPS+IFN- γ or IL-4, followed by luteolin exposure for 24 h. Supernatants were harvested and levels of IL-6 (A) and IL-10 (B) secreted from the M-polarized BMDM were measured via ELISA. Data represented mean $\pm$ SD of four independent experiments performed in duplicate. Different symbols indicate a significant difference according to ANOVA and Tukey test. * $P < 0.05$ vs. Control group (without treatment); & $P < 0.05$ vs. LPS+IFN- γ -treated group.

Effect of luteolin on the expression of surface markers on polarized BMDM. CD11c and CD206 are the surface marks of M1-polarized or M2-polarized BMDM, respectively. FCM results elevated that the MFI of CD11c (60.81) in M1-polarized BMDM was significantly enhanced compared with that of IL-4 treatment group (13.84) and Control group (11.59). The MFI of CD206 (58.36) in M2-polarized BMDM was also significantly amplified than that in LPS+IFN- γ alone treatment group (12.46) and Control group (7.33). Against this, luteolin treatment dramatically attenuated the CD11c MFI to 29.56 (LPS+IFN- γ +2.5Lut-treated group) and 23.02 (LPS+IFN- γ +5.0Lut-treated group) in M1-polarized BMDM, but gradually strengthened the CD206 MFI to 16.12 (LPS+IFN- γ +2.5 Lut-treated group) and 38.77 (LPS+IFN- γ +5.0 Lut-treated group) in M1-polarized BMDM in a concentration-dependent pattern (Fig.7).

238

239 **FIG 7** Effects of luteolin on the expression of BMDM surface markers CD11c and CD206. The
240 BMDM were stimulated with LPS+IFN- γ or IL-4, and then luteolin treatment for 24 h, the
241 expression levels of CD11c (A) and CD206 (B) protein on BMDM are presented as MFI as
242 evaluated by FCM. The histogram presents the MFI of CD11c (C) and CD206 (D). Data
243 represented mean $\pm$ SD of three independent experiments performed in triplicate. Different
244 symbols indicate a significant difference according to ANOVA and Tukey test. * $P < 0.05$ vs.
245 Control group (without treatment); & $P < 0.05$ vs. LPS+IFN- γ -treated group.

246 **Effect of luteolin on protein pathway in polarized BMDM.** STAT signaling proteins exert a
247 vital role in macrophage polarization and the expression of inflammatory cytokines in sepsis.
248 Immunoblotting assay and densitometry analysis of STAT proteins revealed that M1-polarized

249 BMDM highly expresses p-STAT1 and lowly expresses p-STAT6, whereas M2-polarized BMDM
250 lowly expresses p-STAT1 and highly expresses p-STAT6. Predominantly, after luteolin
251 contribution, p-STAT1 expression was depressed while p-STAT6 was strengthened in protein
252 pathway of M1-polarized BMDM (Fig. 8).

254 **FIG 8** Effects of luteolin on the protein levels of p-STAT1/6 in polarized BMDM. The BMDM
255 were primed with LPS+IFN- γ or IL-4, and then for addition of luteolin for 24 h. Total cell lysates
256 were analyzed by immunoblotting for the indicated antibody, respectively. β -Actin was used as
257 loading control. Representative immunoblots of p-STAT1 (A) and p-STAT6 (B); The relative
258 protein levels of p-STAT1 and p-STAT6 (D) by densitometric analysis. Data represented mean $\pm$
259 SD of three independent experiments. Different symbols indicate a significant difference
260 according to ANOVA and Tukey test. * P < 0.05 vs. Control group (without treatment); & P < 0.05
261 vs. LPS+IFN- γ -treated group.

DISCUSSION

Infectious diseases are the leading cause of death, and the infection severity is due to an exaggerated activation of macrophages and cytokine storm (15). LPS, the main component of endotoxin, is the outer membrane structure of cell wall of Gram-negative bacteria which can bind to toll-like receptor 4 (TLR4) on macrophage surface to induce M1 polarization and secrete pleiotropic cytokines. IFN- γ can synergy with LPS to further activate cells, secrete excessive cytokines, cause SIRS, and severe cases cause sepsis and MOF (7). Therefore, it is particularly important to regulate macrophage polarization, avoid excessive activation of M1 macrophages, reduce inflammation and promote tissue repair. BMDM are suitable cell models for studying macrophage polarization. In this investigation, bone marrow cells derived from femur of C57BL/6 mice were stimulated to develop and differentiate into mature BMDM by M-CSF. LPS and IFN- γ stimulated BMDM to undergo M1 polarization, and M1-type pro-inflammatory factors including iNOS, TNF, IL-6 and surface markers CD86 and CD11C were up-regulated; IL-4 stimulated BMDM M2 polarization, and M2-type anti-inflammatory factors including Arg1, IL-10 and CD206 were up-regulated, indicating successful induction of M1/2 polarization in BMDM. After luteolin contribution, the M1-type pro-inflammatory factors decreased and the M2-type anti-inflammatory factors increased evidently in M1-polarized BMDM. Concurrently, the protein pathway p-STAT1 expression was down-regulated and p-STAT6 expression was up-regulated. It suggests that luteolin may modulate the phenotype polarization of BMDM through the inhibition of p-STAT1 and the activation of p-STTA6, transforming it from pro-inflammatory M1-type to anti-inflammatory M2-type, thereby reducing the expression of inflammatory mediators and alleviating inflammation to maintain the stability of the microenvironment.

Cell polarization is regulated by various signaling molecules or transcription factors. STATs are one of the pivotal signal transduction pathways and widely involved in the process of cell activation, apoptosis, inflammation and immune regulation (16). Studies by Sodhi et al. (17) and Zhou et al. (18) showed that IL-6 and IFN- γ released by LPS-polarized M1 macrophages can promote the expression of STAT1 protein, and that IFN- γ can also motivate STAT1 by binding to its receptor, and simultaneously, the activated STAT1 can further provoke the levels of TNF- α , IL-1 β and iNOS in macrophages. iNOS, is a signature of M1-polarized macrophages, which responsible for nitric oxide (NO) production when cells are stimulated by IFN- γ or LPS, and excessive NO causes oxidative stress and inflammatory damage (19). Both CD86 and CD11c are surface markers of M1 macrophages. CD86 is a B7 costimulatory molecule that stimulates the activation of antigen-presenting cells to secrete more pro-inflammatory factors. In the meantime, the level of CD86 can reflect and positively correlate with the level of cytokines such as IFN- γ and IL-12, while IL-10 can hinder the level of CD86 (20-210). CD11c is often coupled with CD18 and binds to bacterial LPS, which activates CD4⁺T cells to proliferate and differentiate into Th1 cells and secrete massive TNF- α , IL-6 and IL-12 to trigger inflammatory cascades (22). Two other crucial cytokines IL-6 and TNF- α , generated abundantly by IL-1 β stimulation or autocrine from activated “mononuclear-macrophage system”, are elevated not only in bacterial infection but also during viral infection (23-24). More importantly, they are most strong pro-inflammatory agent causing “cytokine storm”. Studies have shown that patients with severe COVID-19 characterized by a “cytokine storm” inexorably exhibited high levels of IL-6 and TNF- α in serum, and IL-6 or TNF- α antagonist seems to be very promising for severe COVID-19 cases (25-26).

To our knowledge, IL-4 or IL-13 can induce M2-type polarization of macrophages, and

306 M2-type anti-inflammatory factors such as IL-10, Arg1 and CD206 are up-modulated. In this
307 regard, IL-4 binds to its receptor to activate JAK to further phosphorylate STAT6 and enhance the
308 Arg1 activity. Arg1 and iNOS are important hallmarks of M2/M1 type macrophage polarization,
309 respectively. Under normal circumstances, the activities of Arg1 and iNOS are strictly regulated
310 by macrophages and maintain a dynamic equilibrium. When M2 polarization occurs, Arg1
311 competes for iNOS to decompose substrate arginine, thus benefit for tissue regeneration.
312 Moreover, Arg1 is also inseparable from M2 macrophage properties in playing immune memory
313 function to eliminate infectious agents. CD206, so called mannose receptor, is a membrane surface
314 marker of M2 cells, which can specifically recognize antigens to clear pathogens, promote
315 angiogenesis and repress immune response (27). Another M2-type anti-inflammatory factor, IL-10,
316 on the one hand, enhances the sensitivity of macrophages to IL-4 and IL-13 by increasing the
317 abundance of IL-4 receptors on the macrophage surface, which contributes to M2-type
318 polarization of macrophages. On the other hand, it can synergize with IL-4 to inhibit
319 pro-inflammatory cytokines IL-1 β and TNF- α to reduce inflammation. In the light of preliminary
320 data, IL-10 displayed higher levels in patients with sepsis and serious COVID-19 (28). All these
321 indicate that when inflammation is motivated, an intricate network is formed between the
322 pro-inflammatory mediators and activated STAT1, eliciting "inflammatory storm." Nevertheless,
323 upon luteolin contribution, a complex network is also formed between anti-inflammatory
324 mediators and activated STAT6, further facilitating the expression of anti-inflammatory factors
325 which resist the formation of pro-inflammatory factors and alleviate inflammation accordingly.
326 Herbal compound Physalin D can repolarize M1 toward M2 polarization in BMDM through
327 STAT1 suppression and STAT6 activation (29), which consist with our study.

Altogether, BMDM polarization mechanism is complex and involves many protein pathways. Only by actively exploring the regulation of BMDM polarization and maintaining the balance of inflammatory mediators can maintain the physical stable. In this investigation, LPS/IFN- γ induced M1 polarization and IL-4 induced M2 polarization of BMDM. After being treated with herbal compound luteolin, the M1 polarized BMDM showed lowered M1-type pro-inflammatory factors and elevated M2-type anti-inflammatory factor, and that signaling protein p-STAT1 was down-regulated and P-STAT6 was up-regulated. That is, the macrophage population underwent a transformation from a pro-inflammatory M1-phenotype to an anti-inflammator M2-phenotype. Simultaneously, inflammatory factors analogously altered from pro-inflammatory to anti-inflammatory. In light of these findings, our research provide a novel insight into the role of luteolin to be a candidate for controlling macrophage phenotype to treat infectious disease.

ACKNOWLEDGEMENTS

We acknowledge the support of their staff and Facility of department of Endocrine and Metabolism in accomplishing this work. We also thank Dr. C. M. (Cao Meng) and Z. J. (Zhou Jing) for carrying out exploratory experiments and valuable advice. W. S. (Wang Shuxia) wrote the manuscript. Moreover, L. X. (Li Xingjia), M. X. (Mao Xiaodong), Y.W. (Yang Wanwei) and C. G. (Chen Guofang) edited this manuscript and analyzed data.

This work was supported by National Natural Science Foundation of China (grant number 81673945; 81471010) and the Project of Jiangsu Branch of China Academy of Chinese Medical Sciences (FY201809).

349 The authors declare there are no competing interests.

350 REFERENCES

351 1. Chousterman BG, Swirski FK, Weber GF. 2017. Cytokine storm and sepsis disease
352 pathogenesis. *Semin Immunopathol* 39:517-528. <https://doi.org/10.1007/s00281-017-0639-8>.

353 2. Greten FR, Grivennikov SI. 2019. Inflammation and cancer: triggers, mechanisms, and
354 consequences. *Immunity* 51:27-41. <https://doi.org/10.1016/j.immuni.2019.06.025>.

355 3. Zhang R, Wang XB, Ni L, Di X, Ma BT, Niu S, Liu CW, Russel J. Reiter. COVID-19:
356 Melatonin as a potential adjuvant treatment. *Life Sciences* 250 (2020): 117583.
357 <https://doi.org/10.1016/j.lfs.2020.117583>.

358 4. Li H, Liu L, Zhang DY, Xu JY, Dai HP, Tang N, Su X, Cao B. 2020. SARS-CoV-2 and viral
359 sepsis: observations and hypotheses. *Lancet* 395:1517-1520. [https://doi.org/10.1016/S0140-6736\(20\)30920-X](https://doi.org/10.1016/S0140-6736(20)30920-X).

361 5. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A,
362 Mekinian A, Anunciacion-Llunell A, Miró-Mur F. 2020. Immunomodulatory therapy for the
363 management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review.
364 *Autoimmun Rev* 19:102569. <https://doi.org/10.1016/j.autrev.2020.102569>.

365 6. Liu Q, Zhou YH, Yang ZQ. 2016. The cytokine storm of severe influenza and development of
366 immunomodulatory therapy. *Cell Mol Immunol* 13:3-10. <https://doi.org/10.1038/cmi.2015.74>.

367 7. Wang, SX, Cao M, Xu SH, Zhang JM. Wang ZG, Mao XD, Yao XM, Liu C. 2017. Effect of
368 luteolin on inflammatory responses in RAW264.7 macrophages activated with LPS and IFN- γ . *J*

- 369 Funct Foods 32: 123-130. [https://doi: 10.1016/j.jff.2017.02.018](https://doi.org/10.1016/j.jff.2017.02.018).
- 370 8. Banu N, Panikar SS, Leal LR, Leal AR. 2020. Protective role of ACE2 and its downregulation
371 in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications.
372 Life Sci 256:117905. [https://doi: 10.1016/j.lfs.2020.117905](https://doi.org/10.1016/j.lfs.2020.117905). (Online ahead of print)
- 373 9. Wong TY, Tan YQ, Lin SM, Leung LK. 2017. Apigenin and luteolin display differential
374 hypocholesterolemic mechanisms in mice fed a high-fat diet. Biomed Pharmacother 96:1000-1007.
375 [https://doi: 10.1016/j.biopha.2017.11.131](https://doi.org/10.1016/j.biopha.2017.11.131).
- 376 10. Yao Y, Rao C, Zheng G, Wang S. 2019. Luteolin suppresses colorectal cancer cell metastasis
377 via regulation of the miR-384/pleiotrophin axis. Oncol Rep 42:131-141. [https://doi:](https://doi.org/10.3892/or.2019.7136)
378 [10.3892/or.2019.7136](https://doi.org/10.3892/or.2019.7136).
- 379 11. Kim SH, Saba E, Kim BK, Yang WK, Park YC, Shin HJ, Han CK, Lee YC, Rhee MH. 2018.
380 Luteolin attenuates airway inflammation by inducing the transition of CD4(+)CD25(-) to
381 CD4(+)CD25(+) regulatory T cells. Eur J Pharmacol 820:53-64. [https://doi:](https://doi.org/10.1016/j.ejphar.2017.12.003)
382 [10.1016/j.ejphar.2017.12.003](https://doi.org/10.1016/j.ejphar.2017.12.003).
- 383 12. Yan H, Ma L, Wang H, Wu S, Huang H, Gu Z, Jiang J, Li Y. 2019. Luteolin decreases the yield
384 of influenza A virus in vitro by interfering with the coat protein I complex expression. J Nat Med
385 73:487-496. [https://doi: 10.1007/s11418-019-01287-7](https://doi.org/10.1007/s11418-019-01287-7).
- 386 13. Peng M, Watanabe S, Chan KWK, He Q, Zhao Y, Zhang Z, Lai X, Luo D, Vasudevan SG, Li
387 G. 2017. Luteolin restricts dengue virus replication through inhibition of the proprotein convertase
388 furin. Antiviral Res 143:176-185. [https://doi: 10.1016/j.antiviral.2017.03.026](https://doi.org/10.1016/j.antiviral.2017.03.026).
- 389 14. Huang YF, Bai C, He F, Xie Y, Zhou H. 2020. Review on the potential action mechanisms of

390 chinese medicines in treating coronavirus disease 2019 (COVID-19). *Pharmacol Res* 158:104939.

391 [https://doi: 10.1016/j.phrs.2020.104939](https://doi.org/10.1016/j.phrs.2020.104939). (Online ahead of print)

392 15. Srikiatkachorn A , Mathew A , Rothman AL. 2017. Immune-mediated cytokine storm and its

393 role in severe dengue. *Semi Immunopathol* 39: 563-574. [https://doi: 10.1007/s00281-017-0625-1](https://doi.org/10.1007/s00281-017-0625-1).

394 16. Alhetheel A, Yakubtsov Y, Abdkader K, Sant N, Diaz-Mitoma F, Kumar A, Kryworuchko M.

395 2008. Amplification of the signal transducer and activator of transcription I signaling pathway and

396 its association with apoptosis in monocytes from HIV-infected patients. *AIDS* 22:1137-1144.

397 [https://doi: 10.1097/QAD.0b013e3283013d42](https://doi.org/10.1097/QAD.0b013e3283013d42).

398 17. Sodhi A, Keshewani V. 2007. Signaling molecules involved in production and regulation of

399 IL-1beta by murine peritoneal macrophages in vitro on treatment with concanavalin A. *Int*

400 *Immunopharmacol* 7: 1403-1413. [https:// doi: 10.1016/j.intimp.2007.07.004](https://doi.org/10.1016/j.intimp.2007.07.004).

401 18. Zhou DX, Huang C, Lin Z, Zhan SX, Kong LN, Fang CB, Li J. 2014. Macrophage

402 polarization and function with emphasis on the evolving roles of coordinated regulation of cellular

403 signaling pathways. *Cell Signal* 26: 192-197. [https://doi: 10.1016/j.cellsig.2013.11.004](https://doi.org/10.1016/j.cellsig.2013.11.004).

404 19. Rath M, Müller I, Kropf P, Closs EI, Munder M. 2014. Metabolism via arginase or nitric oxide

405 synthase: two competing arginine pathways in macrophages. *Front Immunol* 5:532. [https://doi:](https://doi.org/10.3389/fimmu.2014.00532)

406 [10.3389/fimmu.2014.00532](https://doi.org/10.3389/fimmu.2014.00532).

407 20. Philipp D, Suhr L, Wahlers T, Choi YH, Paunel-Görgülü A. 2018. Preconditioning of bone

408 marrow-derived mesenchymal stem cells highly strengthens their potential to promote

409 IL-6-dependent M2b polarization. *Stem Cell Res Ther* 9:286. [https://doi:](https://doi.org/10.1186/s13287-018-1039-2)

410 [10.1186/s13287-018-1039-2](https://doi.org/10.1186/s13287-018-1039-2).

- 411 21. Soltys J, Bonfield T, Chmiel J, Berger M. 2002. Functional IL-10 deficiency in the lung of
412 cystic fibrosis (cftr(-/-)) and IL-10 knockout mice causes increased expression and function of B7
413 costimulatory molecules on alveolar macrophages. J Immunol 168: 1903-1910. [https://doi:](https://doi:10.4049/jimmunol.168.4.1903)
414 [10.4049/jimmunol.168.4.1903](https://doi:10.4049/jimmunol.168.4.1903).
- 415 22. Sándor N, Lukácsi S, Ungai-Salánki R, Orgován N, Szabó B, Horváth R, Erdei A, Bajtay Z.
416 2016. CD11c/CD18 dominates adhesion of human monocytes, macrophages and dendritic cells
417 over CD11b/CD18. Plos One 11:e0163120. [https://doi: 10.1371/journal.pone.0163120](https://doi:10.1371/journal.pone.0163120).
- 418 23. Indalao IL, Sawabuchi T, Takahashi E, Kido H. 2017. IL-1 β Is a key cytokine that induces
419 trypsin upregulation in the influenza virus-cytokine-trypsin cycle, Arch Virol 162:201-211.
420 [https://doi: 10.1007/s00705-016-3093-3](https://doi:10.1007/s00705-016-3093-3).
- 421 24. Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS. 2020. IL-6: relevance for
422 immunopathology of SARS-CoV-2. Cytokine Growth F R 53:13-24. [https://doi:](https://doi:10.1016/j.cytogfr.2020.05.009)
423 [10.1016/j.cytogfr.2020.05.009](https://doi:10.1016/j.cytogfr.2020.05.009).
- 424 25. Tufan A, Güler AA, Matucci-Cerinic M. 2020. COVID-19, immune system response,
425 hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 50:620-632. [https://doi:](https://doi:10.3906/sag-2004-168)
426 [10.3906/sag-2004-168](https://doi:10.3906/sag-2004-168).
- 427 26. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, Richards D, Hussell
428 T. 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet
429 395:1407-1409. [https://doi: 10.1016/S0140-6736\(20\)30858-8](https://doi:10.1016/S0140-6736(20)30858-8).
- 430 27. Dai K, Huang L, Sun XM, Yang LH, Gong ZJ. 2015. Hepatic CD206-positive macrophages

- 431 express amphiregulin to promote the immunosuppressive activity of regulatory T cells in HBV
432 infection. J Leukoc Biol 98: 1071-1080. [https://doi: 10.1189/jlb.4A0415-152R](https://doi.org/10.1189/jlb.4A0415-152R).
- 433 28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T,
434 Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R,
435 Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel
436 coronavirus in Wuhan, China. Lancet 395:497-506. [https://doi: 10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- 437 29. Ding N, Wang YX, Dou C, Liu FL, GuanG, Wei KY, Yang JY, Yang MC, Tan J, Zeng W, Zhu
438 CH. 2019. Physalin D regulates macrophage M1/M2 polarization via the STAT1/6 pathway. J Cell
439 Physiol 234:8788-8796. [https://doi: 10.1002/jcp.27537](https://doi.org/10.1002/jcp.27537).